Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Abeona Therapeutics stock | 1.31

Own Abeona Therapeutics stock in just a few minutes.


Fact checked

Abeona Therapeutics Inc is a biotechnology business based in the US. Abeona Therapeutics shares (ABEO) are listed on the NASDAQ and all prices are listed in US Dollars. Abeona Therapeutics employs 88 staff and has a trailing 12-month revenue of around USD$7 million.

How to buy shares in Abeona Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Abeona Therapeutics. Find the stock by name or ticker symbol: ABEO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abeona Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.31, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Abeona Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Abeona Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Abeona Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Abeona Therapeutics's share price has had significant negative movement.

Its last market close was USD$1.31, which is 67.65% down on its pre-crash value of USD$4.05 and 3.05% down on the lowest point reached during the March crash when the shares fell as low as USD$1.35.

If you had bought USD$1,000 worth of Abeona Therapeutics shares at the start of February 2020, those shares would have been worth USD$890.41 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$598.17.

Abeona Therapeutics share price

Use our graph to track the performance of ABEO stocks over time.

Abeona Therapeutics shares at a glance

Information last updated 2020-11-19.
Latest market close USD$1.31
52-week range USD$0.99 - USD$4.34
50-day moving average USD$1.2056
200-day moving average USD$2.3276
Wall St. target price USD$6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.586

Buy Abeona Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Abeona Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abeona Therapeutics price performance over time

Historical closes compared with the close of $1.31 from 2020-10-19

1 week (2020-11-19) -2.24%
1 month (2020-10-27) 11.02%
3 months (2020-08-27) -42.29%
6 months (2020-05-27) -60.30%
1 year (2019-11-26) -55.21%
2 years (2018-11-26) -84.40%
3 years (2017-11-24) -92.18%
5 years (2015-11-25) -72.01%

Abeona Therapeutics financials

Revenue TTM USD$7 million
Gross profit TTM USD$-48,566,000
Return on assets TTM -20.87%
Return on equity TTM -80.35%
Profit margin 0%
Book value $1.362
Market capitalisation USD$132 million

TTM: trailing 12 months

Shorting Abeona Therapeutics shares

There are currently 3.5 million Abeona Therapeutics shares held short by investors – that's known as Abeona Therapeutics's "short interest". This figure is 31.8% up from 2.6 million last month.

There are a few different ways that this level of interest in shorting Abeona Therapeutics shares can be evaluated.

Abeona Therapeutics's "short interest ratio" (SIR)

Abeona Therapeutics's "short interest ratio" (SIR) is the quantity of Abeona Therapeutics shares currently shorted divided by the average quantity of Abeona Therapeutics shares traded daily (recently around 2.5 million). Abeona Therapeutics's SIR currently stands at 1.36. In other words for every 100,000 Abeona Therapeutics shares traded daily on the market, roughly 1360 shares are currently held short.

However Abeona Therapeutics's short interest can also be evaluated against the total number of Abeona Therapeutics shares, or, against the total number of tradable Abeona Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abeona Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Abeona Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0494% of the tradable shares (for every 100,000 tradable Abeona Therapeutics shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abeona Therapeutics.

Find out more about how you can short Abeona Therapeutics stock.

Abeona Therapeutics share dividends

We're not expecting Abeona Therapeutics to pay a dividend over the next 12 months.

Have Abeona Therapeutics's shares ever split?

Abeona Therapeutics's shares were split on a 1:50 basis on 24 October 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Abeona Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Abeona Therapeutics shares which in turn could have impacted Abeona Therapeutics's share price.

Abeona Therapeutics share price volatility

Over the last 12 months, Abeona Therapeutics's shares have ranged in value from as little as $0.99 up to $4.34. A popular way to gauge a stock's volatility is its "beta".

ABEO.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abeona Therapeutics's is 1.447. This would suggest that Abeona Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Abeona Therapeutics overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site